Lung cancer has long been one of the most challenging cancers to treat, often diagnosed at advanced stages when treatment options are limited. However, the treatment landscape is rapidly evolving with the introduction of immunotherapy for early-stage lung cancer. This breakthrough transforms outcomes and offers new hope to patients and their families.
Lung cancer remains one of the leading causes of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 80-85% of cases.1 Traditionally, early-stage NSCLC treatment involved surgery followed by chemotherapy, which is associated with a modest improvement in overall survival of just 5%. Over the past decade, advancements in treatment strategies have aimed to improve survival rates and reduce recurrence risk. Recent clinical trials have led to a paradigm shift, incorporating immunotherapy in both neoadjuvant and adjuvant treatment settings, in combination with chemotherapy in the neoadjuvant setting or given after chemotherapy.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
